Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
48,446,966

-0.41 (-1.43%)

Updated Aug 16, 2024 04:01 PM ET

After-Market: $28.27 -0.03 (-0.11%) 5:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications

Merck & Co., Inc. (MRK) announced that the FDA has approved two new indications for Keytruda (pembrolizumab), the company's anti-PD-1 therapy.

    Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

    Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

      Endocyte (ECYT) Focused on Two Lead Pipeline Candidates

      We issued an updated report on Endocyte, Inc. (ECYT) on May 17.

        J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021

        Johnson & Johnson, Inc. (JNJ) discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts.

          The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific

          The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific

            Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status

            Sangamo Therapeutics, Inc. (SGMO) announced that the FDA has granted fast track designation to pipeline candidate, SB-525.

              5 Reasons Why Merck (MRK) is a Good Stock to Buy Now

              It looks like a great stock to buy now.

                Sheraz Mian headshot

                Stock Market Today & Home Depot, Pfizer and ConocoPhillips Research Reports

                Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Home Depot (HD) and ConocoPhillips (COP).

                  Aerie's (AERI) Rhopressa NDA Sufficient for FDA Review

                  Aerie Pharmaceuticals, Inc. (AERI) announced that it has received notification from the FDA about the completion of the initial 60-day review of the NDA for Rhopressa

                    What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

                    Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

                      Arpita Dutt headshot

                      Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study

                      While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.

                        Model N (MODN) Q2 Loss Narrower than Expected, Guides Well

                        Model N, Inc. (MODN) reported second-quarter 2017 adjusted loss of 25 cents per share, which was wider than the year-ago quarter's loss of 21 cents.

                          Arpita Dutt headshot

                          Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit

                          Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.

                            Swarup Gupta headshot

                            Dow 30 Stock Roundup: Apple, Merck Beat; Pfizer Misses on Revenues

                            The Dow traded inside a tight band during a week marked by key earnings releases and legislative developments.

                              Merck vs. Pfizer: Which Stock Looks Better Post-Earnings?

                              Pfizer is better positioned than Merck and thus calls for investors' attention post earnings.

                                Aerie (AERI) Posts Wider-Than-Expected Q1 Loss, Expenses Up

                                Aerie Pharmaceuticals, Inc. (AERI) posted first-quarter 2017 loss of 76 cents per share (including stock-based compensation), wider than the Zacks Consensus Estimate of a loss of 74 cents.

                                  Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat

                                  Momenta Pharmaceuticals Inc. (MNTA) reported loss of 46 cents per share in the first quarter of 2017,which was narrower than the Zacks Consensus Estimate loss of $1.09. In fact, the company posted a loss of 35 cents in the year-ago quarter as well.

                                    Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More

                                    Here we have four pharma companies that are set to report first-quarter results on May 4. Let's see how things are shaping up for them.

                                      Merck (MRK) Beats on Q1 Earnings & Sales, Ups Annual View

                                      Merck & Co., Inc. (MRK) reported first-quarter 2017 earnings of 88 cents per share, which beat the Zacks Consensus Estimate of 83 cents.

                                        Pfizer and Apple In Focus

                                        Pfizer and Apple In Focus

                                          Mark Vickery headshot

                                          On Pfizer and Apple: 2 Titanic Stocks Reporting Earnings Today

                                          Instead of another run-down of the high number of companies reporting today, I'd like to focus on one company having reported before the bell and one coming after the close: Pfizer (PFE) and Apple (AAPL).

                                            Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact

                                            Pfizer, Inc. (PFE) reported first-quarter 2017 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 67 cents by 3%.

                                              Zacks Investment Ideas feature highlights: Tesla, Pfizer, Apple and Facebook

                                              Zacks Investment Ideas feature highlights: Tesla, Pfizer, Apple and Facebook

                                                Pfizer (PFE) Tops Q1 Earnings Estimates, Misses Sales

                                                PFE beat first quarter earnings which came in at 69 cents while our consensus called for EPS of 67 cents.

                                                  Drug Stocks Q1 Earnings Slated for May 2: MRK, PFE & GILD

                                                  The Q1 earnings season is in full swing with financial results from 288 S&P 500 members or 63.8% of the index already out as of Apr 28, 2017.